The respiratory tract is an attractive target organ for novel diagnostic and therapeutic applications with nano-sized carriers, but their immune effects and interactions with key resident antigenpresenting cells (APCs) such as dendritic cells (DCs) and alveolar macrophages (AMs) in different anatomical compartments remain poorly understood. Polystyrene particles ranging from 20 nm to 1,000 nm were instilled intranasally in BALB/c mice, and their interactions with APC populations in airways, lung parenchyma, and lung-draining lymph nodes (LDLNs) were examined after 2 and 24 hours by flow cytometry and confocal microscopy. In the main conducting airways and lung parenchyma, DC subpopulations preferentially captured 20-nm particles, compared with 1,000-nm particles that were transported to the LDLNs by migratory CD11b low DCs and that were observed in close proximity to CD3 1 T cells. Generally, the uptake of particles increased the expression of CD40 and CD86 in all DC populations, independent of particle size, whereas 20-nm particles induced enhanced antigen presentation to CD41 T cells in LDLNs in vivo. Despite measurable uptake by DCs, the majority of particles were taken up by AMs, irrespective of size. Confocal microscopy and FACS analysis showed few particles in the main conducting airways, but a homogeneous distribution of all particle sizes was evident in the lung parenchyma, mostly confined to AMs. Particulate size as a key parameter determining uptake and trafficking therefore determines the fate of inhaled particulates, and this may have important consequences in the development of novel carriers for pulmonary diagnostic or therapeutic applications.Keywords: nanoparticles; uptake; trafficking; dendritic cells; alveolar macrophagesIn the area of innovative biomedical applications, the potential benefits of manufactured nanoparticles have been increasingly recognized. In particular, nano-sized carriers have been proposed as promising novel diagnostic, therapeutic, and vaccination approaches to a variety of human diseases (1-4). The sitespecific delivery of diagnostic molecules, drugs, vaccines, peptides, and genes through nano-sized carrier systems offers potential advantages, including fewer systemic side effects (5). Another potential advantage of particulate delivery systems involves their "natural" targeting to antigen-presenting cells (APCs). The delivery of nano-sized carriers to the lung has been receiving increasing interest because of the large surface area provided by the gas-exchange region, limited local proteolytic activity (6), noninvasiveness, and fine anatomical barriers for systemic access (7,8). Shape, surface-charge modifications, and particle sizes are key determinants governing the fate of particles within the respiratory tract. Inhaled particles deposit in a sizedependent manner in the respiratory tract (9-11). Smaller particle sizes reach alveolar spaces of the lung parenchyma (LP) (12, 13), and their clearance from the respiratory tract is delayed (14) because of the absence of an ...